This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Comparing Pradaxa® (dabigatran etexilate) and Warfarin Skip to main content
  • References:
  • 1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Connolly SJ, Wallentin L, Yusuf S. Additional events in the RE-LY Trial [Letter to the Editor] N Engl J Med. 2014;371(15):1464-1465.
  • 3. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157-164.
  • 4. PRADAXA [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
  • 5. Coumadin® (warfarin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2011.
  • 6. Jonas DE, Shilliday BB, Laundon WR, Pignone M. Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making. 2010;30(2):206-216.
  • 7. Leung TS, Fradette M, Thompson A, Koshman SL. Dabigatran in atrial fibrillation: new kid on the block. Can Pharm J (Ott). 2012;145(2):83-87.
  • 8. Hanley CM, Kowey PR. Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? J Thorac Dis. 2015;7(2):165-171.